!!Johann de Bono - Biography
\\
Professor de Bono is a world leading clinician-scientist in cancer research, having published more than 600 manuscripts that have been cited >110,000 times with an H-Index of 147 in November 2023. His work has transformed cancer care on multiple occasions and has added hundreds of thousands of life years to cancer patients. Professor de Bono is a world leader in prostate cancer research, having changed its treatment multiple times, through trials of abiraterone, cabazitaxel, enzalutamide, olaparib and lutetium PSMA. He is committed to transforming the care of cancer sufferers by conducting hypothesis-testing, biomarker-driven, proof-of-concept, clinical trials, as evidenced by his track record which includes publications in Nature, Science, Cell, NEJM and The Lancet. \\
\\
Professor de Bono's efforts have led him to become the Head of Division of Clinical Studies at The Institute of Cancer Research (ICR), an independent college of The University of London, and the Royal Marsden Hospital (RMH) where he co-founded and leads The Royal Marsden Drug Development Unit and The ICR/RMH Experimental Cancer Medicine Centre team. In addition, Professor de Bono founded and leads the the RM Prostate Cancer Targeted Therapy Group team. \\
\\
Professor de Bono has led on the clinical development of multiple PARP inhibitors including talazoparib, niraparib and olaparib; his work on PARP inhibitors for sufferers of advanced prostate resulted in our recognizing that germline and somatic DNA repair defects are common in lethal prostate cancer. Professor de Bono also co-led studies mapping the genomic landscape of advanced prostate cancer, also showing how circulating biomarkers can be used for managing these diseases. His work also changed international guidelines on germline testing in men with advanced prostate cancer, and has resulted in the first molecular stratification for this commonest of male cancers.\\ \\[{ALLOW view All}][{ALLOW edit jdebono}][{ALLOW upload jdebono}][{ALLOW comment All}]